Alnylam Pharmaceuticals has been granted a patent for a double-stranded RNA molecule that targets the Serum Amyloid A gene, inhibiting its expression. The RNA molecule consists of a sense and antisense strand, each 15-30 nucleotides long, with the antisense strand complementary to the SAA mRNA sequence. GlobalData’s report on Alnylam Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Alnylam Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Alnylam Pharmaceuticals, siRNA gene silencing was a key innovation area identified from patents. Alnylam Pharmaceuticals's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Inhibiting expression of serum amyloid a gene

Source: United States Patent and Trademark Office (USPTO). Credit: Alnylam Pharmaceuticals Inc

A recently granted patent (Publication Number: US11884919B2) discloses a double-stranded ribonucleic acid (dsRNA) designed to target and inhibit the expression of Serum amyloid A (SAA) mRNA. The dsRNA consists of a sense strand and an antisense strand, each 15-30 nucleotides in length, with the antisense strand containing a region complementary to the SAA mRNA sequence. The patent also covers modified nucleotides in the dsRNA, including various chemical modifications like 2'-0-methyl, phosphorothioate, and cholesteryl derivatives, among others.

Furthermore, the patent includes claims related to the length and structure of the dsRNA, such as the presence of a dTdT overhang, the specific nucleotide sequences of the sense and antisense strands, and the potential conjugation of the dsRNA to a ligand for targeted delivery. The patent also extends to applications of the dsRNA, including its use in pharmaceutical compositions for inhibiting SAA gene expression, as well as in vectors and cells for research purposes. Notably, the patent highlights the effectiveness of the dsRNA in inhibiting SAA mRNA and protein expression, with significant reductions observed in both cell-based assays and mouse models compared to control treatments.

To know more about GlobalData’s detailed insights on Alnylam Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies